Aziz ur Rehman, Hafiz2015-12-101360-0834http://hdl.handle.net/1885/51979The issue of TRIPS-plus standards and its implications of access to essential medicines are discussed in this article in the Indian context. As a leading country in the manufacture and supply of generic drugs, the case of India is crucial when consideredKeywords: Access to medicines; Free trade agreements; India; Patent law; Pharmaceutical patents; TRIPS201010.1080/13600834.2010.5334572016-02-24